Reports of Biochemistry
and Molecular Biology
Wed, Jul 30, 2025
[Archive]
Volume 13, Issue 4 (Vol.13 No.4 Jan 2025)
rbmb.net 2025, 13(4): 474-483 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Khdir Hamad A, Hamad Shareef S, Hameed Saeed C, Kamal Kheder R, Dhahir Majeed P. Procalcitonin Level and Antimicrobial Resistance among Microbial Coinfection in Hospitalized COVID-19 Patients. rbmb.net 2025; 13 (4) :474-483
URL: http://rbmb.net/article-1-1538-en.html
URL: http://rbmb.net/article-1-1538-en.html
Abdulqadr Khdir Hamad 
, Suhayla Hamad Shareef * , Chiman Hameed Saeed , Ramiar Kamal Kheder , Pshtiwan Dhahir Majeed
, Suhayla Hamad Shareef * , Chiman Hameed Saeed , Ramiar Kamal Kheder , Pshtiwan Dhahir Majeed
Department of Biology, College of Education, Salahaddin University-Erbil, Erbil 44001, Kurdistan Region, Iraq & Department of Medical Analysis, Faculty of Applied Science, Tishk International University, Erbil 44001, Kurdistan Region, Iraq.
Abstract: (346 Views)
Background: Hospitalized Coronavirus Disease 2019 (COVID-19) patients are at a higher risk of bacterial and fungal infections. Procalcitonin is an inflammatory marker that has been suggested for distinguishing between bacterial and viral infections that predicting bacterial co-infection in COVID-19 and serving as a helpful indicator for determining the severity of the illness. This study aimed to evaluate procalcitonin levels and antimicrobial resistance (AMR) among microbial co-infections in hospitalized COVID-19 patients.
Methods: Clinical and microbiological data were obtained from the medical records of 100 COVID-19 patients.
Results: COVID-19 patients with bacterial infections had a 55% mortality rate. The majority of microbial cultures were detected in blood (49%), sputum (44%), and urine (7%). Among the isolates, 57.7% were Gram-negative bacteria, 31.7% were Gram-positive bacteria, 6.7% were mixed isolates, and 3.8% were fungal isolates. The predominant Gram-negative isolates were Klebsiella pneumoniae (37.2%), Acinetobacter baumannii (20.2%), and Streptococcus pneumoniae (14.4%). Candida albicans (2.9%) was the most commonly isolated fungal pathogen, followed by Aspergillus spp. (1%). Most of the isolates showed high resistance to broad-spectrum antibiotics. Gram-negative bacteria were detected in 29% of COVID-19 patients who died, Gram-positive bacteria in 20%, and mixed bacteria in 6%. The majority of surviving patients had procalcitonin levels below 0.25 ng/mL, whereas non- survivors had higher levels.
Conclusion: Secondary microbial infections in COVID-19 patients remain a critical concern during the pandemic. Additionally, multidrug-resistant organisms are an increasing challenge. In hospitalized COVID-19 patients, baseline procalcitonin levels were associated with patient outcomes and bacterial coinfection.
Methods: Clinical and microbiological data were obtained from the medical records of 100 COVID-19 patients.
Results: COVID-19 patients with bacterial infections had a 55% mortality rate. The majority of microbial cultures were detected in blood (49%), sputum (44%), and urine (7%). Among the isolates, 57.7% were Gram-negative bacteria, 31.7% were Gram-positive bacteria, 6.7% were mixed isolates, and 3.8% were fungal isolates. The predominant Gram-negative isolates were Klebsiella pneumoniae (37.2%), Acinetobacter baumannii (20.2%), and Streptococcus pneumoniae (14.4%). Candida albicans (2.9%) was the most commonly isolated fungal pathogen, followed by Aspergillus spp. (1%). Most of the isolates showed high resistance to broad-spectrum antibiotics. Gram-negative bacteria were detected in 29% of COVID-19 patients who died, Gram-positive bacteria in 20%, and mixed bacteria in 6%. The majority of surviving patients had procalcitonin levels below 0.25 ng/mL, whereas non- survivors had higher levels.
Conclusion: Secondary microbial infections in COVID-19 patients remain a critical concern during the pandemic. Additionally, multidrug-resistant organisms are an increasing challenge. In hospitalized COVID-19 patients, baseline procalcitonin levels were associated with patient outcomes and bacterial coinfection.
Type of Article: Original Article |
Subject:
Microbiology
Received: 2024/12/25 | Accepted: 2025/02/8 | Published: 2025/07/30
Received: 2024/12/25 | Accepted: 2025/02/8 | Published: 2025/07/30
References
1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5] [PMID]
2. Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. JAMA pediatrics. 2020;174(9):882-9. [DOI:10.1001/jamapediatrics.2020.1467] [PMID]
3. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971-7. e3. [DOI:10.1016/j.immuni.2020.04.023] [PMID] []
4. Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan XG. Bacterial and fungal infections in COVID-19 patients: A matter of concern. Infect Control Hosp Epidemiol. 2020;41(9):1124-1125. [DOI:10.1017/ice.2020.156] [PMID] []
5. Lim YK, Kweon OJ, Kim HR, Kim TH, Lee MK. Impact of bacterial and viral coinfection in community-acquired pneumonia in adults. Diagn Microbiol Infect Dis. 2019;94(1):50-54. [DOI:10.1016/j.diagmicrobio.2018.11.014] [PMID] []
6. Shaveisi-Zadeh F, Nikkho B, Khadem Erfan MB, Amiri A, Azizi A, Mansouri N, et al. Changes in liver enzymes and association with prognosis in patients with COVID-19: a retrospective case- control study. J Int Med Res. 2022;50(7):03000605221110067. [DOI:10.1177/03000605221110067] [PMID] []
7. Mostafa-Hedeab G. ACE2 as drug target of COVID-19 virus treatment, simplified updated review. Rep Biochem Mol Biol. 2020;9(1):97. [DOI:10.29252/rbmb.9.1.97] [PMID] []
8. Rostami-Far Z, Rahmani K, Mansouri K, Erfan MBK, Shaveisi-Zadeh F, Nikkhoo B. Genetic Regulation of Interleukin-6 and Interleukin-10 in COVID-19 Infection. Rep Biochem Mol Biol. 2023;12(2):284. [DOI:10.61186/rbmb.12.2.284] [PMID] []
9. Grasselli G, Cattaneo E, Florio G. Secondary infections in critically ill patients with COVID-19. Crit Care. 2021;25(1):317. [DOI:10.1186/s13054-021-03672-9] [PMID] []
10. Silva DL, Lima CM, Magalhães VC, Baltazar LM, Peres NT, Caligiorne RB, et al. Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients. J Hosp Infect. 2021;113:145-54. [DOI:10.1016/j.jhin.2021.04.001] [PMID] []
11. Khurana S, Singh P, Sharad N, Kiro VV, Rastogi N, Lathwal A, et al. Profile of co-infections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian J Med Microbiol. 2021;39(2):147-53. [DOI:10.1016/j.ijmmb.2020.10.014] [PMID] []
12. De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I, et al. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infect Dis. 2022;22(1):207. [DOI:10.1186/s12879-022-07192-x] [PMID] []
13. Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist. 2021;14:1893. [DOI:10.2147/IDR.S299774] [PMID] []
14. Nori P, Cowman K, Chen V, Bartash R, Szymczak W, Madaline T, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infect Control Hosp Epidemiol. 2021;42(1):84-8. [DOI:10.1017/ice.2020.368] [PMID] []
15. Senok A, Alfaresi M, Khansaheb H, Nassar R, Hachim M, Al Suwaidi H, et al. Coinfections in patients hospitalized with COVID-19: a descriptive study from the United Arab Emirates. Infect Drug Resist. 2021;14:2289. [DOI:10.2147/IDR.S314029] [PMID] []
16. Balkhair A, Al-Muharrmi Z, Al'Adawi B, Al Busaidi I, Taher H, Al-Siyabi T, et al. Prevalence and 30-day all-cause mortality of carbapenem-and colistin-resistant bacteraemia caused by Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae: description of a decade-long trend. Int J Infect Dis. 2019;85:10-5. [DOI:10.1016/j.ijid.2019.05.004] [PMID]
17. Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J J Infect. 2020;81(2):266-75. [DOI:10.1016/j.jinf.2020.05.046] [PMID] []
18. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021;2(8):e354-e65. [DOI:10.2139/ssrn.3786694]
19. Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. [DOI:10.1016/j.jcv.2020.104364] [PMID] []
20. Mishra K, Mishra P, Singh A, Singh S. Impact of COVID-19 pandemic on anti-microbial resistance and secondary microbial infections. Int J Clin Virol. 2021;5(1):032-6. [DOI:10.29328/journal.ijcv.1001032]
21. Stefanini I, De Renzi G, Foddai E, Cordani E, Mognetti B. Profile of Bacterial Infections in COVID-19 Patients: Antimicrobial Resistance in the Time of SARS-CoV-2. Biology. 2021;10(9):822. [DOI:10.3390/biology10090822] [PMID] []
22. Almagor J, Temkin E, Benenson I, Fallach N, Carmeli Y; DRIVE-AB consortium. The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model. PLoS One. 2018;13(5): e0197111. [DOI:10.1371/journal.pone.0197111] [PMID] []
23. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID]
24. Atallah NJ, Warren HM, Roberts MB, Elshaboury RH, Bidell MR, Gandhi RG, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study. PLoS one. 2022;17(1):e0262342. [DOI:10.1371/journal.pone.0262342] [PMID] []
25. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. [DOI:10.1056/NEJMoa2002032] [PMID] []
26. Williams EJ, Mair L, de Silva TI, Green DJ, House P, Cawthron K, et al. Evaluation of procalcitonin as a contribution to antimicrobial stewardship in SARS-CoV-2 infection: a retrospective cohort study. J Hosp Infect. 2021;110:103-107. [DOI:10.1016/j.jhin.2021.01.006] [PMID] []
27. Nazar Hasan Anber Z, Oead Mohammed Saleh B, Waheab Al-Obidy M. Hepatocellular Damage and Severity of COVID-19 Infection in Iraqi Patients: A Biochemical Study. Rep Biochem Mol Biol. 2022;11(3):524-531. [DOI:10.52547/rbmb.11.3.524] [PMID] []
28. Abavisani M, Rahimian K, Kodori M, Khayami R, Sisakht MM, Mahmanzar M, et al. In silico analysis of the substitution mutations and evolutionary trends of the SARS-CoV-2 structural proteins in Asia. Iran J Basic Med Sci. 2022;25(11):1299.
29. Saeed CH, Shareef SH, Majeed PD. Prevalence of Helicobacter pylori Infection in Cigarette and Nargileh Smoking Males in Erbil City, Iraq. Al-Anbar Med J. 2022;18(2):72-6. [DOI:10.33091/amj.2022.176309]
30. Hassan PA, Hameed Saeed C, Rashid SA, Sorchee SM, Shareef SH. Identification of Streptococcus sanguinis genes producing biofilm from gingivitis. Cell Mol Biol (Noisy-le-grand). 2022;68(8):34-40. [DOI:10.14715/cmb/2022.68.8.6] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
